Chrystelle Lamagna
About Chrystelle Lamagna
Chrystelle Lamagna serves as the Director of Translational Biology at Terray Therapeutics, where she leads the in vivo pharmacology team. With a strong background in cell biology and immunology, she has extensive experience in drug discovery and has contributed to significant advancements in the field.
Current Role at Terray Therapeutics
Chrystelle Lamagna serves as the Director of Translational Biology at Terray Therapeutics since 2022. In this role, she leads the in vivo pharmacology team, managing 6 to 8 direct reports. She formulates in vivo pharmacology strategies that advance drug discovery programs from target validation through Investigational New Drug (IND) application. Her work focuses on evaluating and characterizing novel small molecules in models of peripheral and central inflammation.
Previous Experience at Rigel Pharmaceuticals
Prior to her current position, Chrystelle Lamagna worked at Rigel Pharmaceuticals Inc. as Executive Director of Biology from 2014 to 2022. During her eight years at Rigel, she contributed to various projects in the field of biology, leveraging her expertise in pharmacology and drug discovery.
Postdoctoral Fellowship at UCSF
Chrystelle Lamagna completed her postdoctoral fellowship at the University of California, San Francisco (UCSF) from 2009 to 2014. This five-year tenure allowed her to deepen her knowledge and skills in translational biology, contributing to her subsequent roles in the pharmaceutical industry.
Educational Background
Chrystelle Lamagna earned her Master’s degree in Cell Biology, Immunology, and Microbiology from Aix-Marseille University, studying from 1996 to 2001. She furthered her education at the University of Geneva, where she obtained her Ph.D. in Cell Biology and Immunology from 2001 to 2005. Her academic background laid the foundation for her extensive career in translational biology.
Contributions to Drug Discovery
At Terray Therapeutics, Chrystelle Lamagna played a key role in the discovery and characterization of an oral RIPK1 inhibitor for inflammatory diseases in collaboration with Eli Lilly. She also contributed to the elaboration of IND reports and supported regulatory filings, showcasing her expertise in navigating the drug development process.